Roche fined for hindering entry of generic cancer drugs

Romania’s Competition Council has fined F. Hoffmann-La Roche’s local subsidiary €12.8 million for abusing its dominance in multiple cancer treatment markets, but the drugmaker has accused the enforcer of acting in bad faith and ignoring evidence of its innocence.


Get unlimited access to all Global Competition Review content